Rat Monoclonal Antibody to SARS CoV2 RdRp

Researchers at the University of Pittsburgh have developed a novel rat monoclonal antibody targeting a specific peptide epitope on the SARS CoV2 RNA-dependent RNA polymerase (RdRp) protein. RdRp is essential for viral replication and is the target for antiviral drugs such as remdesivir. This antibody is highly specific and compatible with various laboratory techniques, including immunoblotting, immunofluorescence assays (IFA), immunohistochemistry (IHC), and immunoprecipitation. This breakthrough offers a valuable tool for basic research on SARS CoV2, potential drug discovery, and as a diagnostic reagent.

Description

The technology involves the creation of a rat monoclonal antibody that specifically binds to a peptide epitope on the SARS CoV2 RdRp protein. This antibody is the first of its kind and provides a new avenue for researchers to study the replication machinery of the virus. The antibodies can be used in a variety of applications, from identifying and studying protein interactions to serving as a diagnostic tool for detecting the presence of the RdRp protein in infected cells.

Applications

- Basic Research
- Drug Discovery
- Diagnostic Reagent

Advantages

This rat monoclonal antibody provides a unique and specific tool for researchers working on SARS CoV2. It supports multiple research techniques, making it a versatile addition to the laboratory toolkit. As the first monoclonal antibody against SARS CoV2 RdRp, it fills a critical gap in research and diagnostic capabilities, aiding in the fight against COVID-19.

Invention Readiness

The antibody has been validated in vitro, with ongoing collaborations to further its development. The invention is ready for licensing and commercialization opportunities, providing a valuable resource for both research and clinical applications.

IP Status

Research Tool